SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Cleland W)
 

Sökning: WFRF:(Cleland W) > (2005-2009) > A comparison of the...

  • Cleland, J. G. (författare)

A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)

  • Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2006

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/50152
  • https://gup.ub.gu.se/publication/50152URI
  • https://lup.lub.lu.se/record/693348URI
  • https://doi.org/10.1016/j.jacc.2005.11.069DOI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • OBJECTIVES: This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET). BACKGROUND: The ultimate objectives of treating patients with heart failure are to relieve suffering and prolong life. Although the effect of treatment on mortality is usually described in trials, the effects on patient well-being throughout the trials' courses are rarely reported. METHODS: A total of 3,029 patients randomized in the COMET study were included in the analysis. "Patient journey" was calculated by adjusting days alive and out of hospital over four years using a five-point score completed by the patient every four months, adjusted according to the need for intensification of diuretic therapy. Scores ranged from 0% (dead or hospitalized) to 100% (feeling very well). RESULTS: Over 48 months, 17% of all days were lost through death, 1% through hospitalization, 23% through impaired well-being, and 2% through the need for intensified therapy. Compared with metoprolol, carvedilol was associated with fewer days lost to death, with no increase in days lost due to impaired well-being or days in hospital. The "patient journey" score improved from a mean of 54.8% (SD 26.0) to 57.4% (SD 26.3%) (p < 0.0068). CONCLUSIONS: Despite treatment with beta-blockers, heart failure remains associated with a marked reduction in well-being and survival. Loss of quality-adjusted life-years through death and poor well-being seemed of similar magnitude over four years, and both were much larger than the loss that could be attributed to hospitalization.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Charlesworth, A. (författare)
  • Lubsen, J. (författare)
  • Swedberg, Karl,1944Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine(Swepub:gu)xsweka (författare)
  • Remme, W. J. (författare)
  • Erhardt, Leif RWLund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups(Swepub:lu)medf-ler (författare)
  • Di Lenarda, A. (författare)
  • Komajda, M. (författare)
  • Metra, M. (författare)
  • Torp-Pedersen, C. (författare)
  • Poole-Wilson, P. A. (författare)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för akut och kardiovaskulär medicin (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of the American College of Cardiology: Elsevier BV47:8, s. 1603-111558-35970735-1097

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy